#Canada #Vancouver #BioVaxys #DPX Technology #GMP-grade Lipid

BioVaxys' Strategic Move in Vaccine Development

BioVaxys Technology Corp. has taken a major step forward in its quest to advance vaccine technology. The company is pleased to announce the acquisition of a substantial supply of 48 kilograms of GMP-grade lipids, essential for the production of its DPX antigen delivery platform. This acquisition comes as BioVaxys prepares to revitalize its clinical studies and kick off new preclinical trials.

Previously produced by IMV, Inc. for anticipated clinical trials, these lipids have now found a new home at BioVaxys following its purchase of all related intellectual properties and programs in February 2024. This strategic move positions the company to save over a year in manufacturing time and aligns with its goals of conducting a variety of preclinical and clinical trials in the near future.

What is DPX Technology?

BioVaxys' patented DPX™ technology is designed to offer an innovative way to package and deliver a wide array of bioactive molecules, including mRNA, peptides, and even virus-like particles. Its unique delivery mechanism allows for targeted immune responses, leveraging a non-aqueous and non-systemic platform. This technology promotes the recruitment of immune cells at the injection site, facilitating the uptake of antigens to regional lymph nodes. The end goal? A robust and enduring immune response against the delivered antigens.

Kenneth Kovan, the President and Chief Operating Officer of BioVaxys, expressed optimism regarding the lipid acquisition, praising the commercially attractive terms. He stated, "With 48 kg of lipid anticipated to cover production for any conceivable preclinical or clinical trials over the next several years, this strategic investment is crucial for our development pipeline."

BioVaxys's Clinical Pipeline

BioVaxys is dedicated to harnessing its DPX™ technology for various medical applications, including cancer treatment and potential solutions for infectious diseases and allergies. One of its key clinical trials focuses on MAVEROPEPIMUT-S (MVP-S), which is in Phase IIB trials for advanced relapsed-refractory diffuse large B-cell lymphoma (DLBCL) as well as platinum-resistant ovarian cancer. This treatment uses survivin—an antigen often overexpressed in advanced cancers—to stimulate an immune response.

In addition to MVP-S, BioVaxys is pursuing other projects, including the DPX™+SurMAGE, aimed at developing immunotherapies targeting both survivin and MAGE-A9. The company's efforts also encompass the treatment for Respiratory Syncytial Virus and peanut allergies, showcasing its diverse focus in immunological research.

Future Prospects

As BioVaxys forges ahead with its clinical programs, the company is keenly aware of the challenges inherent in bringing biopharmaceutical products to market. While there is significant potential for its innovative therapies, factors such as regulatory approvals, clinical efficacy, and market acceptance will play critical roles in determining future success.

The company's shares are publicly listed on the Canadian Securities Exchange under the symbol 'BIOV', as well as on the Frankfurt Bourse and OTCQB in the United States, enhancing its profile within the global biotech marketplace.

As BioVaxys continues to advance its vaccine development programs with this new lipid supply, all eyes will be on the outcomes of its clinical trials and the innovative applications of its unique DPX technology.

Conclusion

The acquisition of GMP-grade lipids marks a pivotal moment for BioVaxys, potentially accelerating its drug development timeline and solidifying its commitment to innovative immunotherapies. With the company’s focus on delivering targeted and lasting immune responses, its future endeavors in vaccine technology could hold significant promise for improved health outcomes worldwide.